BioCardia Receivables 2010-2024 | BCDA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioCardia receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioCardia receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$150.5B
Bristol Myers Squibb (BMY)	$118.1B
Vertex Pharmaceuticals (VRTX)	$115.4B
Gilead Sciences (GILD)	$109.4B
CSL (CSLLY)	$85.4B
Regeneron Pharmaceuticals (REGN)	$81.8B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$34.4B
Alnylam Pharmaceuticals (ALNY)	$30.2B
BioNTech SE (BNTX)	$25.5B
Biogen (BIIB)	$22.6B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$18.3B
Moderna (MRNA)	$14.3B
Incyte (INCY)	$13.6B
Genmab (GMAB)	$13.6B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$11.8B
Vaxcyte (PCVX)	$10.9B
Bio-Techne Corp (TECH)	$10.5B
Sarepta Therapeutics (SRPT)	$10.2B
Exact Sciences (EXAS)	$10B
Exelixis (EXEL)	$9.8B
Revolution Medicines (RVMD)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
QIAGEN (QGEN)	$9.3B
Intra-Cellular Therapies (ITCI)	$8.8B
Roivant Sciences (ROIV)	$8.4B
Ascendis Pharma (ASND)	$7.5B
Repligen (RGEN)	$7.2B